Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. More Details
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has Hemcheck Sweden's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HEMC is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: HEMC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: HEMC underperformed the Swedish Medical Equipment industry which returned 19.7% over the past year.
Return vs Market: HEMC underperformed the Swedish Market which returned 18.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Hemcheck Sweden's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StIs Hemcheck Sweden (STO:HEMC) In A Good Position To Invest In Growth?
6 months ago | Simply Wall StDid Changing Sentiment Drive Hemcheck Sweden's (STO:HEMC) Share Price Down By 32%?
7 months ago | Simply Wall StHow Many Hemcheck Sweden AB (publ) (STO:HEMC) Shares Did Insiders Buy, In The Last Year?
Is Hemcheck Sweden undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HEMC is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: HEMC is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HEMC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HEMC is good value based on its PB Ratio (1.3x) compared to the SE Medical Equipment industry average (4.5x).
How is Hemcheck Sweden forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemcheck Sweden has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Hemcheck Sweden's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Hemcheck Sweden competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Hemcheck Sweden performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HEMC is currently unprofitable.
Growing Profit Margin: HEMC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HEMC is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
Accelerating Growth: Unable to compare HEMC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HEMC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (49.3%).
Return on Equity
High ROE: HEMC has a negative Return on Equity (-27.13%), as it is currently unprofitable.
How is Hemcheck Sweden's financial position?
Financial Position Analysis
Short Term Liabilities: HEMC's short term assets (SEK10.7M) exceed its short term liabilities (SEK2.4M).
Long Term Liabilities: HEMC's short term assets (SEK10.7M) exceed its long term liabilities (SEK154.0K).
Debt to Equity History and Analysis
Debt Level: HEMC's debt to equity ratio (1.2%) is considered satisfactory.
Reducing Debt: HEMC's debt to equity ratio has reduced from 78.7% to 1.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HEMC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HEMC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.8% each year
What is Hemcheck Sweden current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HEMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HEMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HEMC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HEMC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HEMC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Joen Averstad serves as a Chief Executive Officer at Hemcheck Sweden AB (publ) since May 2019.
|Chief Executive Officer||1.5yrs||no data||0.22% |
|Chief Financial Officer||4.83yrs||no data||no data|
|Chief Technology Officer||6.83yrs||no data||0.032% |
|Sales & Marketing Manager and Deputy CEO||2.83yrs||no data||no data|
|Clinical Specialist||no data||no data||0.016% |
Experienced Management: HEMC's management team is considered experienced (3.8 years average tenure).
|Director||10.83yrs||no data||1.45% |
|Deputy Director||5.83yrs||no data||0.032% |
|Independent Director||4.83yrs||no data||0.051% |
|Independent Director||2.83yrs||no data||0.19% |
|Independent Director||4.83yrs||no data||0.032% |
|Independent Chairman||2.83yrs||no data||0.31% |
Experienced Board: HEMC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hemcheck Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Hemcheck Sweden AB (publ)
- Ticker: HEMC
- Exchange: OM
- Founded: 2010
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: kr45.083m
- Shares outstanding: 15.71m
- Website: https://www.hemcheck.com
Number of Employees
- Hemcheck Sweden AB (publ)
- Karlstads universitet
- Värmland County
- 651 88
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HEMC||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Mar 2017|
Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergen...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/01 19:49|
|End of Day Share Price||2020/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.